Genitope has reported that the FDA has granted fast-track status to MyVax, a potential non-Hodgkin's lymphoma treatment. Genitope is investigating whether MyVax, a personalized immunotherapy, improves patients with follicular non-Hodgkin's lymphoma, or fNHL.

MyVax is currently in a Phase III pivotal trial involving stage 3/4 fNHL patients. Results from a Phase II trial showed nine of 21 patients remained progression-free up to 78 months post-chemotherapy.